CFTR and cystic fibrosis: Identification of small molecules that rescue F508del-CFTR defect resulted in the approval of three corrector drugs currently available for individuals with CF: VX-809 (lumacaftor), VX-661 (tezacaftor) or VX-445 (elexacaftor—combined with VX-661), all used in combination with VX-770 (ivacaftor), a gating potentiator [11,12,13].